Ascendis Pharma A/S to Present at Three Upcoming Investor Conferences

COPENHAGEN, Denmark, Sept. 3, 2015 /PRNewswire/ -- Ascendis Pharma A/S (Nasdaq: ASND), a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical needs, today announced plans to present at several upcoming investor conferences.

Event:

2015 Wells Fargo Healthcare Conference in Boston

Date:

Thursday, September 10, 2015 

Time:

1:55pm EDT

Event:

Bank of America Merrill Lynch Global Healthcare Conference in London

Date:

Wednesday, September 16, 2015 

Time:

11:25am GMT+1

Event:

Leerink Partners Rare Disease Roundtable in New York

Date:

Wednesday, September 30, 2015 

Time:

12:30pm EDT

Links to audio webcasts of the conference presentations will be posted to the Ascendis Pharma website at www.ascendispharma.com when available.

About Ascendis Pharma A/S
Ascendis Pharma is applying its innovative TransCon technology, which combines the benefits of prodrug and sustained release technologies, to develop a pipeline of best-in-class therapeutics that address significant unmet medical needs. The TransCon technology can be applied to existing drug therapies, including proteins, peptides and small molecules, to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug.

The Ascendis Pharma pipeline includes TransCon Growth Hormone, a proprietary program that has completed Phase 2 studies in adults and children with growth hormone deficiency. Ascendis Pharma expects to initiate a Phase 3 pediatric study of TransCon Growth Hormone in mid-2016. Ascendis Pharma is also developing its wholly-owned TransCon Treprostinil for the treatment of pulmonary arterial hypertension. In addition to its proprietary programs, Ascendis Pharma has formed collaborations focused on leading products in large markets that are of strategic importance to its collaboration partners. These collaborations are with Sanofi in diabetes and Genentech in the field of ophthalmology.

Investor contact:
Martin Auster, M.D.
Chief Business Officer
[phone]
[e-mail]

Logo - http://photos.prnewswire.com/prnh/20150824/260617LOGO